PET imaging of osteosarcoma

Journal of Nuclear Medicine

Volumn 44, Issue 6, 2003, Pages 930-942

  Brenner, Winfried ^a   Bohuslavizki, Karl H ^b   Eary, Janet F ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

18F FDG; 18F fluoride ion; Metabolic imaging; Osteosarcoma; PET

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADJUVANT CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; HUMAN; IMAGING; MONITORING; OSTEOSARCOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; BONE TUMOR; CLASSIFICATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METABOLISM; METHODOLOGY; SCINTISCANNING; TUMOR RECURRENCE;

BONE NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OSTEOSARCOMA; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0038500835     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Mirra JM. Osteosarcoma: intramedullary variants. In: Mirra JM, ed. Bone Tumors. Philadelphia, PA: Lea & Febiger; 1989:249-389.
2. American Joint Committee on Cancer. Bone. In: AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott Raven, 1997:143-147.
3. Winkler K, Bieling P, Bielack S, et al. Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry. Clin Orthop. 1991;270:79-86.
4. Bruland OS, Pihl A On the current management of Osteosarcoma: a critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer. 1997;33:1725-1731.
5. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999;341:342-352.
6. Resnick D, Greenway GD. Tumors and tumor-like lesions of bone: imaging and pathology of specific lesions. In. Resnick D, ed. Bone and Joint Imaging. Philadelphia, PA: Saunders, 1996:991-1063.
7. Sundaram M The use of gadolinium in the MR imaging of bone tumors. Semin Ultrasound CT MR 1997;18:307-311.
8. Seeger LL, Gold RH, Chandnani VP. Diagnostic imaging of Osteosarcoma. Clin Orthop. 1991;270:254-263.
9. Dominkus M, Kainberger F, Lang S, Kotz R. Primary malignant bone tumors: clinical aspects and therapy - Vienna Bone Tumor Registry [in German]. Radiologe. 1998;38:472-482.
10. Fletcher BD. Imaging pediatric bone sarcomas: diagnosis and treatment-related issues. Radiol Clin North Am. 1997;35:1477-1494.
11. Focacci C, Lattanzi R, Iadeluca ML, Campioni P. Nuclear medicine in primary bone tumors. Eur J Radiol 1998;27(suppl 1):S123-S131.
12. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review J Clin Oncol. 1994;12:423-431.
13. Kotz R, Ritschl P, Trachtenbrodt J. A modular femur-tibia reconstruction system. Orthopedics. 1986;9:1639-1652.
14. Kotz R, Salzer M. Rotation-plasty for childhood osteosarcoma of the distal part of the femur. J Bone Joint Surg Am 1982;64:959-969.
15. Windhager R, Millesi H, Kotz R Resection-replantation for primary malignant tumours of the arm: an alternative to fore-quarter amputation. J Bone Joint Surg Br 1995;77:176-184.
16. Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma: the Memorial Hospital experience. Cancer. 1992;69:698-708.
17. Picci P, Sangiorgi L, Rougraff BT, et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol. 1994;12:2699-2705.
18. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade Osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-790.
19. Saeter G, Hoie J, Stenwig AE, et al. Systemic relapse of patients with osteogenic sarcoma, prognostic factors for long term survival. Cancer. 1995;75:1084-1093.
20. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Onhop. 1980;153:106-120.
21. Enneking WF, Spanier SS, Goodman MA. Current concepts review, the surgical staging of musculoskeletal sarcoma J Bone Joint Surg Am. 1980;62:1027-1030.
22. Kem KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med. 1988;29:181-186.
23. Adler LP, Blair HF, Makley JT, et al Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med. 1991;32:1508-1512.
24. Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med. 2002;29:1149-1154.
25. Eary JF, Conrad EU. Positron emission tomography in grading soft tissue sarcomas. Semin Musculoskelet Radiol. 1999;3:35-138.
26. Eary JF, Conrad EU, Bruckner JD, et al. Quantitative [F-18] fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res. 1998;4:1215-1220.
27. 18FDG uptake in soft tissue masses Eur J Nucl Med. 1999;26:22-30
28. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med. 1996;37:257-261.
29. Jones DN, McCowage GB, Sostman HD, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 1996;37:1438-1444.
30. Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med. 1999;40:1637-1643.
31. 18F]-fluoro-2-deoxy-D-glucose m oncology. Part IIIb. Therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma. J Cancer Res Clin Oncol. 2001;127:278-285.
32. Franzius C, Sciuk J, Brinkschmidt C, Jurgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med. 2000;25:874-881.
33. Garcia R, Kim EE, Wong FC, et al. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas J Nucl Med. 1996;37:1476-1479.
34. Hicks RJ. Nuclear medicine techniques provide unique physiologic characterization of suspected and known soft tissue and bone sarcomas. Acta Orthop Scand Suppl 1997;273:25-36.
35. 18F]fluorodeoxyglucose. Ann Surg Oncol. 1997;4:57-63.
36. Lucas JD, O'Doherty MJ, Wong JC, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br. 1998;80:441-447.
37. Page RL, Garg PK, Garg S, et al. PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment. J Nucl Med 1994:35:1506-1513.
38. Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia Int J Radiat Oncol Biol Phys 1989;17:985-991.
39. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326-336.
40. 18F- labeled RGD-containing glycopeptide and positron emission tomography Cancer Res. 2001;61:1781-1785.
41. Sordillo PP, Benua RS, Gelbard AS, et al. Imaging of human tumors and organs with N-13-labeled L-methionine. Am J Physiol Imaging. 1986;1:195-200.
42. Doubrovin M, Ponomarev V, Beresten T, et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci USA. 2001;98:9300-9305.
43. Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med. 1991;32:1655-1660.
44. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab. 1985;5:584-590.
45. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7.
46. Gjedde A. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res. 1982;257:237-274.
47. Phelps ME, Huang SC, Hoffman EJ, et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371-388.
48. 18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr. 1993;17:582-589.
49. Kole AC, Nieweg OE, Hoekstra HJ, et al. Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors J Nucl Med 1998;39:810-815.
50. Griffeth LK, Dehdashti F, McGuire AH, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose Radiology. 1992;182:185-194.
51. Dehdashti F, Siegel BA, Griffeth LK, et al. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2- deoxy-D-glucose. Radiology 1996;200:243-247.
52. Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med. 1998;39:250-254.
53. Folpe AL, Lyles RH, Sprouse JT, Conrad EU 3rd, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6:1279-1287.
54. Schulte M, Brecht-Krauss D, Heymer B, et al. Grading of tumors and tumorlike lesions of bone evaluation by FDG PET J Nucl Med. 2000;41:1695-1701.
55. Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology. 2001;219:774-777.
56. Watanabe H, Shinozaki T, Yanagawa T, et al. Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning. J Bone Joint Surg Br 2000;82:760-767.
57. 99mTc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med. 2002;43:1012-1017.
58. Messa C, Landoni C, Pozzato C, Fazio F. Is there a role for FDG PET in the diagnosis of musculoskeletal neoplasms [commentary]? J Nucl Med. 2000;41:1702-1703.
59. Wuismau P, Enneking WF. Prognosis for patients who have osteosarcoma with skip metastasis J Bone Joint Surg Am. 1990;72:60-68.
60. Fletcher BD, Hanna SL. Pediatric musculoskeletal lesions simulating neoplasms. Magn Reson Imaging Clin N Am. 1996;4:721-747.
61. Bhagia SM, Grimer RJ, Davies AM, Mangham DC. Scintigraphically negative skip metastasis in osteosarcoma. Eur Radiol. 1997;7:1446-1448.
62. Franzius C, Daldrup-Link HE, Sciuk J, et al FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol. 2001;12:479-486.
63. Franzius C, Daldrup-Link HE, Wagner-Bohn A, et al. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol. 2002;13:157-160.
64. Franzius C, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy Eur J Nucl Med. 2000;27:1305-1311.
65. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR 2001;177:229-236.
66. Lawrence JA, Babyn PS, Chan HS, et al. Extremity osteosarcoma in childhood: prognostic value of radiologie imaging. Radiology. 1993;189:43-47.
67. Nair N, Ali A, Green AA, et al. Response of osteosarcoma to chemotherapy: evaluation with F-18 FDG-PET scans Clin Positron Imaging 2000;3:79-83.
68. Hawkins DS, Rajendran JG, Conrad EU 3rd, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D- glucose positron emission tomography. Cancer. 2002;94:3277-3284.
69. Abdel-Dayem HM. The role of nuclear medicine in primary bone and soft tissue tumors. Semin Nucl Med. 1997;27:355-363.
70. Fletcher BD. Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation. AJR. 1991;157:825-833.
71. Ma LD, Frassica FJ, Scott WW Jr, Fishman EK, Zerbount EA. Differentiation of benign and malignant musculoskeletal tumors: potential pitfalls with MR imaging. Radiographics. 1995;15:349-366.
72. Lang P, Wendland MF, Saeed M, et al. Osteogenic sarcoma: noninvasive in vivo assessment of tumor necrosis with diffusion-weighted MR imaging. Radiology. 1998;206:227-235.
73. Reddick WE, Bhargava R, Taylor JS, Meyer WH, Fletcher BD Dynamic contrast-enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy. J Magn Reson Imaging. 1995;5:689-694.
74. Reddick WE, Wang S, Xiong X, et al. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma. Cancer. 2001;91:2230-2237.
75. el-Zeftawy H, Heiba SI, Jana S, et al. Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma. Cancer Biother Radiopharm. 2001;16:37-46.
76. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995;333:1380-1385.
77. Baldini N, Scotlandi K, Serra M, et al. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. J Orthop Res 1999;17:629-632.
78. Serra M, Maurici D, Scotlandi K, et al Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma. Int J Oncol. 1999;14:301-307.
79. Green JR, Reeve J, Tellez M, Veall N, Wootton R. Skeletal blood flow in metabolic disorders of the skeleton. Bone. 1987;8:293-297.
80. 18F in rabbit bone Clin Phys Physiol Meas. 1986;7:333-343.
81. Garnett ES, Bowen BM, Coates G, Nahmias C. An analysis of factors which influence the local accumulation of bone-seeking radiopharmaceuticals Invest Radiol. 1975;10:564-568.
82. Nahmias C, Cockshott WP, Belbeck LW, Garnett ES Measurement of absolute bone blood flow by positron emission tomography. Skeletal Radiol. 1986;15:198-200.
83. Hawkins RA, Choi Y, Huang SC, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992;33:633-642.
84. Grynpas MD. Fluoride effects on bone crystals. J Bone Miner Res. 1990;5(suppl 1):S169-S175.
85. Cook GJ, Lodge MA, Marsden PK, Dynes A, Fogelman I. Non-invasive assessment of skeletal kinetics using fluorine-18 fluoride positron emission tomography: evaluation of image and population-derived arterial input functions Eur J Nucl Med. 1999;26:1424-1429.
86. 18F]fluoride ion positron emission tomography. Eur J Nucl Med Mol Imaging. 2002;29:907-914.
87. 18F]fluoride ion positron emission tomography. Eur J Nucl Med. 1999;26:615-624.
88. 18F]fluoride ion PET: correlation with bone histomorphometry. J Nucl Med. 2001;42:1091-1100.
89. Blau M, Nagler W, Bender MA. A new isotope for bone scanning. J Nucl Med. 1962;3:332-334.
90. 18F]fluoride ion and PET. J Comput Assist Tomogr. 1993;17:34-41.
91. Tse N, Hoh C, Hawkins R, Phelps M, Glaspy J. Positron emission tomography diagnosis of pulmonary metastases in osteogenic sarcoma. Am J Clin Oncol. 1994;17:22-25.
92. 18F-labelcd NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800-1804.
93. 18F PET. J Nucl Med. 1999;40:1623-1629.
94. Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography J Clin Oncol 1999;17:2381-2389.